Markets

Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient

Nov 2, 2026 · 01:39 AM ET· updated 2h ago

SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore

Why It Matters

Abbott tested a new heart-cleaning tool on 335 patients. It worked safely and successfully, which is good news for the company.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABT106.25

+1.68 (+1.61%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.